相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Masked polycythemia Vera (mPV): Results of an international study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
JAK2V617F allele burden in patients with myeloproliferative neoplasms
Salem H. Alshemmari et al.
ANNALS OF HEMATOLOGY (2014)
Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?
Magnus Bjorkholm et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
Hajnalka Andrikovics et al.
HAEMATOLOGICA (2014)
Calreticulin mutations and long-term survival in essential thrombocythemia
A. Tefferi et al.
LEUKEMIA (2014)
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
A. Tefferi et al.
LEUKEMIA (2014)
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Raajit Rampal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
James A. Kennedy et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
Gilles Bonicelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Significance of cytogenetic abnormalities in patients with polycythemia vera
Matjaz Sever et al.
LEUKEMIA & LYMPHOMA (2013)
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera
Brady L. Stein et al.
LEUKEMIA & LYMPHOMA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genetic Basis of MPN: Beyond JAK2-V617F
Nicole C. C. Them et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Jelena D. Milosevic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang et al.
BLOOD (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Francesco Passamonti et al.
BLOOD (2012)
Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications
Sandra Malak et al.
BLOOD CELLS MOLECULES AND DISEASES (2012)
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
Krisstina Gowin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Thorsten Klampfl et al.
BLOOD (2011)
The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera
Khadija Abdulkarim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes
Brady L. Stein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
Richard T. Silver et al.
LEUKEMIA RESEARCH (2011)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
Philip A. Beer et al.
BLOOD (2010)
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
Nils H. Thoennissen et al.
BLOOD (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
Omar Abdel-Wahab et al.
CANCER RESEARCH (2010)
Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients
F. Girodon et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy
Francesca Palandri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
Francesca Palandri et al.
LEUKEMIA & LYMPHOMA (2009)
Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera - Single center experience and review of literature
Birgitta Swolin et al.
ANNALS OF HEMATOLOGY (2008)
The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms
Constantine S. Tam et al.
BLOOD (2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Francesco Passamonti et al.
BLOOD (2008)
20+yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
Ayalew Tefferi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Cytogenetic studies at diagnosis in polycythemia vera:: clinical and JAK2V617F allele burden correlates
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications
Anna D. Panani
CANCER LETTERS (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
Jaya Kittur et al.
CANCER (2007)
Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
A. Alvarez-Larran et al.
LEUKEMIA (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera
A. Tefferi et al.
LEUKEMIA (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
D Dingli et al.
CANCER (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
A Tefferi et al.
CANCER (2006)
Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia
CS Chim et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Leukemic transformation of polycythemia vera - A single center study of 23 patients
F Passamonti et al.
CANCER (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders
SM Fruchtman et al.
LEUKEMIA RESEARCH (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
JL Spivak
SEMINARS IN HEMATOLOGY (2004)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
G Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
